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During substrate translocation mitochondrial carriers cycle between the cytoplasmic-state (c-state) with substrate-binding site open to the
intermembrane space andmatrix-state (m-state) with the binding site open to themitochondrial matrix. Here, the accessibility of Cys-58, Cys-136 and
Cys-155 of the rat mitochondrial carnitine/acylcarnitine carrier (CAC) to membrane-impermeable SH reagents was examined as a function of the
conformational state. Reconstituted mutant CACs containing the combinations Cys-58/Cys-136, Cys-58/Cys-155, and Cys-136/Cys-155 transport
carnitine with a ping-pong mechanism like the wild-type, since increasing substrate concentrations on one side of the membrane decreased the
apparent affinity for the substrate on the other side. In view of this mechanism, the effect of SH reagents on the transport activity of mutant CACs was
tested by varying the substrate concentration inside or outside the proteoliposomes, keeping the substrate concentration on the opposite side constant.
The reagents MTSES, MTSEA and fluorescein-5-maleimide did not affect the carnitine/carnitine exchange activity of the mutant carrier with only
Cys-58 in contrast to mutant carriers with Cys-58/Cys-136, Cys-58/Cys-155 or Cys-136/Cys-155. In the latter, the inhibitory effect of the reagents
was more pronounced when the intraliposomal carnitine concentration was increased, favouring the m-state of the carrier, whereas the effect was less
when the concentration of carnitine was increased in the external compartment of the proteoliposomes, favouring the c-state. Moreover, the mutant
carrier proteins with Cys-136/Cys-155, Cys-58/Cys-136 or Cys-58/Cys-155 were more fluorescent when extracted from fluorescein-5-maleimide-
treated proteoliposomes containing 15 mM internal carnitine as compared to 2.5 mM. These results are discussed in terms of conformational changes
of the carrier occurring during substrate translocation.
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The mitochondrial carnitine/acylcarnitine carrier (CAC)
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doi:10.1016/j.bbabio.2007.08.010transports acylcarnitines into the mitochondria in exchange for
free carnitine [1]. The CAC, encoded in man by the gene
SLC25A20, which maps to chromosome 3p21.31 [2], and in
yeast by the gene CRC [3], belongs to a large family of related
transport proteins called the mitochondrial carrier family [4–9].
All primary structures of the family members consist of three
tandemly repeated homologous domains of about 100 amino
acids in length. Each of the three repeats contains two predicted
membrane-spanning regions and a characteristic signature motif
P-X-[DE]-X-X-[RK]. The significant sequence conservation in
the mitochondrial carrier family suggests that the main structural
fold is similar for all carriers and that the specific recognition of
substrates is coupled to a common structural mechanism of
transport [10].
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in mitochondria and in reconstituted liposomes ([11,12] and
references therein). This carrier catalyses carnitine/acylcarnitine
and carnitine/carnitine antiport efficiently and, in the absence of
counter-substrate, 10-fold slower carnitine uniport [13]. The
transporter is inserted unidirectionally in liposomes with a right-
side out orientation compared to mitochondria [14,15]. A single
transport affinity for carnitine was found on each side of the
liposomal membrane with the Km value for external carnitine
being several times lower than that for internal carnitine [14,15].
Both the homologous carnitine/carnitine exchange and the het-
erologous carnitine/acylcarnitine exchange occur via a ping-
pong transport mechanism, implying that only one substrate-
binding site (not necessarily an identical ensemble of amino
acids) is exposed alternatively to the external or the internal side
of the carrier and that the concentration of the substrate on one
side of the membrane influences the apparent affinity for the
substrate on the other side [14]. The structure/function re-
lationship of rat CAC has been investigated by site-directed
mutagenesis of the six native Cys residues. None of these
cysteines is essential for carrier function [15]. Cys-136 is the
major target of SH reagents and is accessible to membrane-
impermeable SH reagents from the external (cytosolic) side of
the proteoliposomes [15]. Furthermore, it was suggested that
Cys-58, Cys-136, and Cys-155 are or come close to each other
during certain steps of the catalytic cycle [12].
It is generally accepted that, during their catalytic transport
cycle, mitochondrial carriers undergo a transition between the
cytoplasmic-state (c-state) and matrix-state (m-state), in which
the substrate-binding site faces the cytosolic side and matrix
side, respectively [16,17]. In the case of the ADP/ATP carrier,
the prototype of the mitochondrial carriers, the structural prop-
erties of the c- and m-states have been investigated by site-
directed mutagenesis and/or chemical modification using two
powerful and state-specific inhibitors: carboxyatractyloside, that
locks the carrier in the c-state, and bongkrekic acid, that locks the
carrier in the m-state [18–22]. The only available high-
resolution structure is that of the ADP/ATP carrier in complex
with carboxyatractyloside, which corresponds most likely to the
c-state [23]. This structure consists of a barrel of six
transmembrane α-helices (H1–H6) and three short α-helices
(h12, h34 and h56) situated in the matrix and parallel to the
membrane plane. The prolines of the signature motif sharply
kink the odd-numbered transmembrane α-helices, and the
charged residues of the motif form a salt bridge network that
closes the cavity where carboxyatractyloside is located on the
matrix side of the protein [23]. This structure has considerably
improved our understanding of the mitochondrial carrier
structure/function relationships. However, further studies are
necessary to elucidate the structural changes occurring during
the transition between the c- and m-states and to better un-
derstand the mechanism of substrate translocation through the
mitochondrial carriers.
In this work, we probed the accessibility/chemical reactivity
of the rat CAC native cysteine residues, Cys-58, Cys-136 and
Cys-155, to membrane-impermeable SH reagents under varia-
tion of external or internal substrate concentrations, i.e., underconditions that change the ratio between the c- and m-states of
the carrier. A strong influence of the conformational state of the
carrier on the accessibility of Cys-136 and Cys-155 to these
reagents is observed.
2. Materials and methods
2.1. Materials
l-[methyl-3H]carnitine and Sephadex G-25 (PD-10) were purchased from
Amersham, MTS reagents from Toronto Research (North York, Ontario,
Canada), Sephadex G-50, G-75 and G-200, egg-yolk phospholipids (l-α-
phosphatidylcholine from fresh turkey egg yolk), Pipes, Triton X-100,
cardiolipin, l-carnitine and N-dodecanoylsarcosine (sarcosyl) from Sigma. All
other reagents were of analytical grade.
2.2. Site-directed mutagenesis, overexpression and isolation of the
CAC proteins
The coding region for the rat CACwas amplified from total rat liver cDNA as
described previously [1]. The Cys/Ser replacements were constructed with
complementary mutagenic primers using the overlap extension method [24] and
the High Fidelity PCR System (Roche). The PCR products were purified using
the Gene Clean Kit (La Jolla), digested with NdeI and HindIII (restriction sites
added at the 5′ end of forward and reverse primers, respectively) and ligated into
the pMW7 expression vector. All mutations were verified by DNA sequencing
and, except for the desired base changes, all of the sequences were identical to
that of rat CAC cDNA. The resulting plasmids were transformed into Escheri-
chia coli C0214 [15]. Bacterial overexpression, isolation of the inclusion body
fraction, and solubilization and purification of the wild-type CAC and mutant
CAC proteins were performed as described previously [15].
2.3. Reconstitution of CAC and CAC mutants in liposomes
The recombinant proteins were reconstituted into liposomes as described
previously [25]; however, the concentration of intraliposomal carnitine was
varied as indicated in the legends to figures. The external substrate was removed
from proteoliposomes on Sephadex G-75 columns.
2.4. Transport measurements
Transport at 25 °C was started by adding [3H]carnitine, at the concentrations
indicated in the legends to figures, to proteoliposomes and terminated by the
addition of 1.5 mM NEM [15,25]. In the case of the mutant C23S/C89S/C136S/
C155S/C283S containing only Cys-58, the reaction was rapidly quenched by
passing the samples through Sephadex G-50 at 2 °C. In controls, the inhibitor
was added together with the labeled substrate, according to the inhibitor stop
method [25]. Finally, the external substrate was removed by chromatography on
Sephadex G-50 columns, and the radioactivity in the liposomes was measured.
The initial transport rate was calculated from the radioactivity taken up by
proteoliposomes after 1 min (in the initial linear range of substrate uptake). The
experimental values were corrected by subtracting control values. All of the
transport activities were determined by taking into account the efficiency of
reconstitution (i.e., the share of successfully incorporated protein).
2.5. Other methods
SDS-PAGE was performed according to Laemmli, as described previously
[15]. The amount of recombinant protein was estimated on Coomassie Blue-
stained SDS-PAGE gels by the Bio-Rad GS-700 Imaging Densitometer
equipped with the Bio-Rad Multi-Analist software using bovine serum albumin
as standard. The extent of incorporation of the recombinant protein into
liposomes was determined as described in Phelps et al. [26] with some mod-
ifications [15]. The homology model of the rat CAC was built based upon the
structure of the bovine AAC1 [23] by using the computer application Swiss
PDB Viewer [27]. A critical determinant in the accuracy of the comparative
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template sequences. AAC1 and CAC were added to sequences from the
mitochondrial carrier family and a multiple sequence alignment was generated
by CLUSTALW. The secondary structure of AAC1 was used to weight the gap
penalties as described previously [10]. One thousand steps of energy
minimization were performed to generate 50 minimized CAC structures. The
structural properties of the CAC models with the best energy function were
evaluated using protein analysis tools available on the WHAT IF Web server
[28]. Final models were examined with PyMOL, VMD and Swiss PDB Viewer
and, where side-chain packing led to clashes, alternative side-chain rotamers
were evaluated.3. Results
3.1. Transport mechanism of CAC mutants
The CAC contains six cysteines: Cys-23, Cys-58, Cys-89,
Cys-136, Cys-155 and Cys-283. Wild-type CAC and CAC
mutants, containing the combinations Cys-58/Cys-136, Cys-58/
Cys-155 and Cys-136/Cys-155 and the other four native
cysteines replaced by serine, were overexpressed in E. coli,
purified and reconstituted into liposomes to measure the
transport rate of carnitine. In the comparative model of CAC,Fig. 1. Structural model of the CAC. Ribbon diagrams viewing the carrier from
the lateral side. The transmembrane α-helices are colored as follows: H1, red;
H2, tan (light brown); H3, green; H4, emerald-green; H5, cyan; and H6, blue.
Purple surfaces highlight the SH groups of the Cys residues indicated by their
number in the CAC sequence. Yellow surfaces highlight the salt bridge network
between residues D32-K135, K35-D231 and E132-K234.
Fig. 2. Bi-substrate analysis of the carnitine/carnitine antiport reaction catalyzed
by reconstituted CAC mutants. Lineweaver–Burk plots showing the depen-
dence of the carnitine/carnitine antiport rate on external carnitine concentration
at three different internal carnitine concentrations. Transport was started by
adding the indicated [3H]carnitine concentrations to liposomes reconstituted
with the C58+C136 mutant (A) or the C58+C155 mutant (B) and preloaded
internally with 2.5 mM (□), 7 mM (•) and 15 mM (○) unlabeled carnitine.
Incubation time was 1 min. The Cys residues present in the mutants are shown.
Similar results were obtained in three independent experiments in duplicate.which was built using the structure of the ADP/ATP carrier in
c-state as template [23], Cys-58, Cys-136 and Cys-155 are
localised below the salt bridge network that closes the central
pore of the α-helical bundle on the matrix side preventing
translocation of the substrate (Fig. 1).
The reconstituted CAC purified from rat liver mitochondria
functions according to a ping-pong mechanism [14]. In this
mechanism [29–32], only one substrate-binding site exists in
the carrier, which is alternatively exposed to the external side
(outward-facing conformation) or to the internal site (inward-
facing conformation) of the membrane. To ascertain whether the
recombinant cysteine mutant carriers follow the same kinetic
mechanism, the carnitine/carnitine exchange activity mediated
by these proteins was measured by varying both external and
internal substrate concentrations. When the kinetic data were
analyzed in Lineweaver–Burk plots (Fig. 2A and B), showing
the dependence of the transport rate on external carnitine at
Fig. 3. Dependence of CAC mutant activity on cardiolipin. Liposomes
reconstituted with wild-type CAC (○), the C58 (•), C136 (▽) or C155 (▴)
CAC mutant, in the presence of the indicated concentrations of cardiolipin, were
preloaded internally with 13 mM carnitine. Transport was started with 0.1 mM
[3H]carnitine and terminated after 10 min. Similar results were obtained in three
independent experiments in duplicate.
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parallel pattern of straight lines was obtained with the CAC four
Cys-replacement mutants C23S/C89S/C155S/C283S (contain-
ing Cys-58 and Cys-136) and C23S/C89S/C136S/C283S (con-
taining Cys-58 and Cys-155). The external Km for carnitine of
mutant C23S/C89S/C155S/C283S was increased from 0.4 to
2.4 mM (Fig. 2A) and that of the mutant C23S/C89S/C136S/
C283S from 0.1 to 1.0 mM (Fig. 2B) on increasing the internal
substrate concentration from 2.5 to 15.0 mM. Clearly, varia-
tion of the substrate concentration in the internal compartment
strongly influences the apparent transport affinity for the
counter-substrate in the external compartment as a consequence
of the change in the instant ratio between outward- and inward-
facing conformations of the carrier protein. Furthermore,
secondary plots of the slopes and ordinate intercepts of
Fig. 2A and B versus the reciprocal concentration of the sub-
strate on the opposite side (not shown) demonstrated that the
ratio of Km/Vmax did not change upon variation of the counter-
substrate concentration. Similar results were obtained with the
wild-type recombinant CAC and with the CAC C23S/C58S/
C89S/C283S mutant containing Cys-136 and Cys-155. Taken
together these results show that all these proteins function
according to a ping-pong mechanism.
3.2. Accessibility of Cys-58 to SH reagents
To investigate the influence of the conformational state of the
carrier on the accessibility of Cys-58, Cys-136 or Cys-155 to
sulphydryl reagents, it would be ideal to use the five Cys-
replacement mutants containing only Cys-58, Cys-136 or Cys-
155. However, all the CAC five Cys-replacement mutants had
been previously found to be inactive [15]. Therefore, we first
attempted to improve the activity of these mutants by adding
increasing amounts of cardiolipin to the mixture used for their
reconstitution into liposomes [11,33,34]. Fig. 3 shows that,
although the wild-type CAC protein exhibited maximal activity
at 200 μg/ml cardiolipin, the five replacement mutants C23S/
C89S/C136S/C155S/C283S, C23S/C89S/C58S/C155S/C283S
and C23S/C58S/C89S/C136S/C283S (containing only Cys-58,
Cys-136 and Cys-155, respectively) were virtually inactive at
this cardiolipin concentration. At 500 μg/ml cardiolipin,
however, the C23S/C89S/C136S/C155S/C283S mutant con-
taining only Cys-58 displayed 40% transport activity compared
to the wild-type CAC, whereas the other two 5 replacement
mutants still exhibited negligible activity. Consequently, after its
reconstitution in the presence of 500 μg/ml cardiolipin, the
C23S/C89S/C136S/C155S/C283S mutant was tested for sensi-
tivity to SH reagents. It was found that the carnitine transport
activity of the mutant, measured as exchange between 0.1 mM
external [3H]carnitine and 2.5 or 15.0mM internal carnitine, was
not affected by 0.5 mM MTSES or MTSEA, whether added
outside the proteoliposomes even 10 min before adding the
labeled substrate or present inside the proteoliposomes, i.e.,
during the reconstitution procedure (data not shown). Similarly,
no effect of 0.5 mM MTSES or MTSEA on the C23S/C89S/
C136S/C155S/C283S mutant was observed when the activity
was measured by adding 0.2 or 5 mM [3H]carnitine to pro-teoliposomes containing 5 mM carnitine. In contrast, NEM
inhibited the activity of the C23S/C89S/C136S/C155S/C283S
mutant by about 80% at 0.5 mM when present in the internal
compartment and had no effect up to 2.0 mMwhen preincubated
externally for 10min with the proteoliposomes (data not shown).
These results indicate that Cys-58 is not accessible to MTSES
and MTSEA, whereas it is accessible to NEM but only from the
internal side of the reconstituted protein.
3.3. Accessibility of Cys-136 and Cys-155 to MTS reagents
under variation of internal and external substrate
concentrations
Given that the five cysteine-replacement mutants C23S/
C89S/C58S/C155S/C283S and C23S/C58S/C89S/C136S/
C283S are inactive and Cys-58 is insensitive to externally
added MTSES and MTSEA, the accessibility of Cys-136 and
Cys-155 to these reagents was investigated in proteoliposomes
reconstituted with one of the four Cys-replacement mutants,
C23S/C89S/C155S/C283S, C23S/C89S/C136S/C283S and
C23S/C58S/C89S/C283S, which contain the combinations
Cys-58/Cys-136, Cys-58/Cys-155 and Cys-136/Cys-155, re-
spectively. In a first set of experiments, MTSES or MTSEAwas
added together with 0.1 mM [3H]carnitine to proteoliposomes
pre-loaded internally with two widely different carnitine
concentrations (2.5 and 15.0 mM) and the initial carnitine/
carnitine exchange rate was measured. The residual transport
activity in the presence of MTSES is shown in Fig. 4A–C. With
all three mutants the inhibition of the transport rate by MTSES
was clearly greater with 15.0 mM than with 2.5 mM internal
carnitine. Furthermore, the mutant containing the Cys-58/Cys-
155 combination was much less sensitive to MTSES than the
mutant containing the Cys-58/Cys-136 combination. Thus, half
maximal inhibition of C23S/C89S/C136S/C283S was obtained
Fig. 5. Effect of MTSES on the activity of the C58+C136, C58+C155 and
C136+C155 mutants at different external carnitine concentrations. Liposomes
were reconstituted with the C58+C136 (A), C58+C155 (B) or C136+C155 (C)
mutant and preloaded internally with 5 mM carnitine. Transport was started by
adding 0.2 mM (□) or 5 mM (n) [3H]carnitine together with the indicated
concentrations of MTSES. Incubation time was 1 min. Results are expressed as
percent of residual activity (i.e., percent of activity in the presence of MTSES
with respect to the control value without inhibitor). The data represent means±
SD of at least three independent experiments in duplicate. The Cys residues
present in the CAC mutants are shown.
Fig. 4. Effect of MTSES on the activity of C58+C136, C58+C155 and C136+
C155 mutants at different intraliposomal carnitine concentrations. Liposomes
reconstituted with the C58+C136 (A), C58+C155 (B) or C136+C155 (C)
mutant were preloaded internally with 2.5 mM (○) or 15 mM (•) carnitine.
Transport was started by adding 0.1 mM [3H]carnitine together with the
indicated concentrations of MTSES and stopped after 1 min. Results are
expressed as percent of residual activity (i.e., percent of activity in the presence
of MTSES with respect to the control value without inhibitor). The data
represent means±SD of at least three independent experiments in duplicate. The
Cys residues present in the CAC mutants are shown.
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that required for half maximal inhibition of C23S/C89S/C155S/
C283S. Similarly to MTSES, MTSEA inhibited the initial
carnitine/carnitine exchange rate catalyzed by the same threemutants more in the presence of 15 mM than 2.5 mM internal
carnitine and also inhibited more Cys-58/Cys-136 than Cys-58/
Cys-155 (data not shown). With the Cys-58/Cys-136 mutant,
4 μMMTSEAyielded total inhibition in the presence of 15 mM
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presence of 2.5 mM internal carnitine; with the Cys-58/Cys-155
mutant, 8 μMMTSEAyielded 67% inhibition in the presence of
15 mM internal carnitine and 47% inhibition in the presence of
2.5 mM. All these results indicate that Cys-136 is more
accessible than Cys-155 to MTSES and MTSEA and that the
accessibility of both Cys residues is greater at the higher internal
carnitine concentration, which favours the inward conformation
of the protein.
In other experiments, the effect of MTSES on the activity of
the four Cys-replacement mutants C23S/C89S/C155S/C283S,
C23S/C89S/C136S/C283S and C23S/C58S/C89S/C283S was
measured in the presence of two different external carnitine
concentrations (0.2 and 5.0 mM) at a constant internal con-
centration of 5.0 mM. MTSES inhibited all three mutants more
with 0.2 mM than with 5.0 mM external carnitine (Fig. 5A–C).
Results similar to those reported in Fig. 5 were obtained using
MTSEA at concentrations up to 8 μM instead of MTSES (data
not shown). Therefore, the accessibility of both Cys-136 and
Cys-155 decreases upon increasing the external concentration,
which favours the outward conformation of the carrier. Fur-
thermore, as observed in the experiments where the substrate
concentration was varied inside the proteoliposomes, the mutant
containing the Cys-58/Cys-155 combination was less sensitive
to MTSEA, and especially to MTSES, than the mutant con-
taining the Cys-58/Cys-136 combination. It should be noted
that the concentrations of substrate used outside and inside theFig. 6. Influence of intraliposomal carnitine concentration on the labeling and inhibi
the C136+C155, C58+C136 or C58+C155 mutant and preloaded internally wit
maleimide, at 10 μM (A and B) and at the indicated concentrations (C) for 1 m
proteoliposomes were passed through Sephadex G-75 columns and ultracentrifuge
precipitated with acetone and subjected to SDS-PAGE. (A) Fluorescence of the UV-ill
carnitine/carnitine exchange activity by fluorescein-5-maleimide. Transport was st
Incubation time was 1 min. Results are expressed as percent of residual activity (i.e.,
control value without inhibitor). The data represent means±SD of three independe
shown. Abbreviation: FM, fluorescein-5-maleimide.proteoliposomes in the experiments of Figs. 4 and 5 were
chosen on the basis of the affinity of the carrier for carnitine on
each side of the liposomal membrane [14,15] and on the fact
that low internal and high external concentrations cannot be
used simultaneously for reliable measurements of radioactive
substrate uptake [25].
3.4. Effect of intraliposomal carnitine concentration on Cys
labeling by fluorescein-5-maleimide
To further support the dependence of Cys-136 and Cys-155
accessibility on the intraliposomal substrate concentration, the
effect of fluorescein-5-maleimide, another impermeable SH
reagent [35], was investigated. In these experiments the mutants
C23S/C58S/C89S/C283S, C23S/C89S/C155S/C283S and
C23S/C89S/C136S/C283S containing Cys-136/Cys-155, Cys-
58/Cys-136 and Cys-58/Cys-155, respectively, were treated
with fluorescein-5-maleimide in reconstituted liposomes under
the two conditions of internal substrate concentration. After-
ward, the mutant proteins were extracted, separated by SDS-
PAGE and either analyzed for fluorescence (Fig. 6A) or stained
with silver nitrate (Fig. 6B). All three CAC mutants were more
fluorescent when extracted from the proteoliposomes containing
15 mM internal carnitine than from the proteoliposomes
containing 2.5 mM carnitine, indicating that the amount of
bound fluorescein-5-maleimide depends on the internal carnitine
concentration. In parallel experiments, reconstituted liposomestion of CAC mutants by fluorescein-5-maleimide. Liposomes reconstituted with
h 2.5 mM or 15 mM unlabeled carnitine were incubated with fluorescein-5-
in at 25 °C; the reaction was then quenched by adding 10 mM DTE. The
d at 110,000×g for 45 min at 4 °C; the pellets were suspended in 2% SDS,
uminated SDS-PAGE gel; (B) silver staining of the same gel; (C) inhibition of the
arted by adding 0.1 mM [3H]carnitine together with fluorescein-5-maleimide.
percent of activity in the presence of fluorescein-5-maleimide with respect to the
nt experiments in duplicate. The Cys residues present in the CAC mutants are
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as in Fig. 6Awere tested for residual transport activity (Fig. 6C).
With all the mutants transport inhibition by fluorescein-5-
maleimide was increased by the presence of the higher intra-
liposomal concentration of carnitine, in agreement with the
labeling results. Furthermore, virtually no labeling or inhibition
by fluorescein-5-maleimide up to 10 μg/ml was detected in the
case of the mutant C23S/C89S/C136S/C155S/C283S contain-
ing only Cys-58 reconstituted in the presence of 500 μg/ml
cardiolipin (data not shown).
4. Discussion
The CAC functions according to a ping-pongmechanism that
implies the existence of two opposite conformations in which the
substrate-binding site is alternatively exposed towards the
cytosol (c-state or outward-facing conformation) or towards
the matrix (m-state or inward-facing conformation). Unfortu-
nately for CAC there are no side-specific ligands available that
fix CAC in one of these conformations, as has been donewith the
ADP/ATP carrier by the addition of carboxyatractyloside or
bongkrekic acid [17,36]. Here we took advantage of the
transport mechanism of CAC, according to which the ratio
between the inward- and the outward-facing conformation of the
carrier can be varied by changing the concentration of the
substrate inside or outside the proteoliposomes, in the presence
of a fixed substrate concentration on the opposite side.
Furthermore, the reconstituted CAC proteins were incubated
with SH reagents only for the time interval used to measure the
initial transport rate in order to limit the number of the catalytic
cycles as much as possible.
The experimental data reported above show that Cys-136 and
Cys-155 of the reconstituted CAC become more accessible to
the membrane-impermeable MTSES, MTSEA or fluorescein-5-
maleimide when the intraliposomal carnitine concentration is
increased, therefore favouring the m-state of the carrier. Alter-
natively, these cysteines become less accessible when the con-
centration of carnitine is increased in the external compartment
of the proteoliposomes, i. e., when the carrier is in the c-state.
The three cysteines whose accessibility has been investigated
here, Cys-58, Cys-136 and Cys-155, are located below the salt
bridge network that in the c-state of the carrier closes the
substrate translocation pathway on the matrix side (Fig. 1).
Given that Cys-136 is located immediately below the salt bridge
between K135 and D32 of the ionic network (Fig. 1), the greater
accessibility of Cys-136 to externally added impermeable
reagents when the majority of CAC molecules are in the m-
state is most likely caused by the opening of the salt bridge
network that must occur during the transition from the c- to the
m-state.
The conformational changes involved in substrate translo-
cation are not yet known. However, it is thought that in the
catalytic cycle of the ADP/ATP carrier the inter-repeat salt
bridges between the charged residues of the three signature
motifs break causing their rearrangement into intra-repeat salt
bridges [37–39] and the stretching of the odd-numbered helices
(H1, H3 and H5) [23] leading to the opening of the translocationchannel. The corresponding inter-repeat salt bridges in rat CAC
are D32-K135, E132-K234 and D231-K35, and the intra-repeat
salt bridges are D32-K35, E132-K135 and D231-K234. The
hypothesized straightening of the odd-numbered helices, in
particular of H3, would make Cys-155 more accessible to
externally added MTSES, MTSEA and fluorescein-5-malei-
mide in the m-state, although Cys-155 may be still partially
screened by H3 in the m-state. This possibility may account for
the lower sensitivity of Cys-155 toward methanethiosulfonate
reagents compared to that of Cys-136. Furthermore, given that
MTSES is negatively charged, the positive charge density of
R133 and K135, that belong to H3 and are close to Cys-155,
may diminish the interaction between MTSES and Cys-155.
In a previous paper, it was shown that the reaction of ex-
ternally added MTSES with Cys-136 of reconstituted CAC is
prevented by the addition of carnitine to proteoliposomes [15]. It
was suggested that Cys-136 is localised at or near the substrate-
binding site. Therefore, the substrate would impede the
interaction of MTSES with Cys-136 either by direct competition
with Cys-136 or by steric hindrance due to binding with side
chains close to Cys-136. The results reported in this work, and in
particular those obtained in the presence of different intralipo-
somal carnitine concentrations, favour the alternative explana-
tion, i.e., that externally added substrate induces a
conformational change of the carrier protein, thereby decreasing
the binding of the inhibitors MTSES, MTSEA and fluorescein-
5-maleimide to a site different from that of the substrate. In this
context it is worth mentioning that acetylcarnitine has been
proposed to bind to F90, R180, D181 and R280 of the S.
cerevisiae CAC [40], corresponding to the residues F86, R178,
D179 and R275 of the rat CAC that are found in the cavity at the
midpoint of the membrane. Unfortunately, it is not possible to
ascertain whether Cys-136 is completely inaccessible in the c-
state because the experimental approach used in this work does
not allow to fix all of the carrier molecules in the same con-
formation. Furthermore, it should be stressed that the confor-
mational change in the carrier can affect not only the
accessibility but also the reactivity of Cys-136 and Cys-155.
This may occur in different ways; for example, a change in the
pK of the side chain of cysteine may take place when the
microenvironment of the sulfhydryl group becomes more
hydrophobic or hydrophilic.
The results obtained using the CAC mutant containing only
Cys-58 clearly show that Cys-58 behaves differently from Cys-
136 and Cys-155 because it is not accessible to MTSES,
MTSEA and fluorescein-5-maleimide in all the experimental
conditions used. This observation can be explained by the CAC
homology model (Fig. 1), as Cys-58 is sterically hindered to
externally added hydrophilic reagents being efficiently screened
by H1. Unlike Cys-155, which is located at the beginning of h34,
Cys-58 is located approximately at the midpoint of h12, and
therefore the stretching of H1 occurring during the transition
from the c-state to the m-state does not increase accessibility to
Cys-58 as does the stretching of H3 to Cys-155. It could be
argued that MTSES, MTSEA and fluorescein-5-maleimide bind
Cys-58 without inhibiting the carrier. An argument in favour of
the conclusion that they do not react with Cys-58 is the
1338 N. Giangregorio et al. / Biochimica et Biophysica Acta 1767 (2007) 1331–1339observation that when present inside the proteoliposomes, NEM
inhibits the CAC mutant containing Cys-58 unlike Cys-less
CAC. The accessibility of Cys-58 to NEM with respect to the
hydrophilic reagents is favoured by the fact that this residue is
surrounded by Y52, F59 and F64 that form an aromatic pocket.
The results of the present study show that the matrix α-helix
of the CAC that connects transmembrane helices H3 andH4, and
contains Cys-136 and Cys-155, undergoes conformational
changes during the catalytic cycle of the carrier. Our data are
in line with the previous finding [21] that the corresponding
region of the ADP/ATP carrier is accessible to externally added
trypsin in a conformational-sensitive manner, being cleaved at
the Lys178–Thr179 bond in the carrier-bongkrekic acid
complex but not in the carrier-carboxyatractyloside complex.
Indeed, positions 178 and 179 of the ADP/ATP carrier
correspond to residues 157 and 158 of the CAC that are very
close to Cys-155. This suggests rather similar conformational
changes in the central matrix loop of the two mitochondrial
carrier proteins.
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